Latest Industry Insights

Technology Networks recently spoke with Gary Kruppa, PhD, Vice President of Proteomics, Bruker Daltonics Inc., to learn more about the advancing research area immunopeptidomics, and to discuss the current status of single cell proteomics.

To learn more about some of the ways that companion diagnostics can benefit oncology patients, Technology Networks spoke to Dr Luca Quagliata, Global Director of Medical Affairs for Clinical NGS and Oncology at Thermo Fisher Scientific.

Technology Networks recently spoke with Ofer Sharon, CEO of OncoHost, to learn more about ways to overcome patient resistance to immunotherapy and how proteomic profiling in oncology can aid diagnosis, prognosis and treatment of this incredibly complex disease.

Lab efficiency is critical to speeding up development processes, yet many researchers find they spend more time managing consumables data than working at the bench. Lab informatics is one solution to this problem.

Image analysis can be a painstaking process for skin cancer pathologists. New technologies are needed to relieve the pressure. We spoke with Nathan Buchbinder, Proscia’s CPO, to find out more about their DermAI software and how it could be part of the solution.

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Cancer immunotherapies and viral vaccines that are nucleic acid-based can be challenging to formulate and require highly specific delivery systems. Commonly adopted delivery systems, such as lipid nanoparticles and viral vectors, can have limitations, therefore alternative approaches are being developed. Technology Networks recently spoke with Nigel Theobald, CEO and Founder of N4 Pharma, to learn more about nanoparticle drug delivery, the Nuvec® platform and its progress towards clinical trials.

With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.

What barriers still exist to the full implementation of next-generation sequencing (NGS) in the diagnostics space, and how can we remove them? Technology Networks recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific, to learn more.

Over the last five to ten years, multi-modal imaging has become established as a significant component of a preclinical researcher’s analytical toolbox. Here, we highlight perhaps the most used and certainly the most sensitive and quantitative of these imaging modalities, the combination of positron emission tomography (PET) with X-ray computed tomography (CT), or PET/CT.